Tumor Cell Targeting

Targeting cancer cell–specific alterations

Cancer cells exhibit differences from somatic cells due to alterations that promote growth, proliferation, survival, and metastasis.1 These tumor-specific attributes can be selectively targeted through established modalities, such as antibody‑drug conjugates (ADCs); small molecules, like Janus kinase (JAK) and bone morphogenetic protein receptor kinase activin A receptor, type I (ACVR1) inhibitors; and other biological therapies.1-4 GSK is investigating targeted cell therapies in ongoing clinical studies.5